In December 2020, the Company entered into a grant contract with the University of Massachusetts Medical School as part of the National Institutes of Health Rapid Acceleration of Diagnostics (“RADx”) initiative to support the Company’s research and development of its diagnostic test for the antigen. The Company has received $1,000 under the grant contract for reimbursement of eligible research and development expenditures.

On January 25, 2022, the Company entered into a contract to amend the Company’s second grant contract under the RADx initiative, which was originally effective February 1, 2021. The purpose of the grant is to support the Company’s manufacturing production and expansion to meet the demand for testing, as well as the Company’s Revogene respiratory panel. The amended contract is a service contract through January 2023, with payment of up to $6,250 being made based on the Company achieving key milestones related to increasing its capacity to produce tests and the Revogene respiratory panel. As of December 31, 2022, $2,750 has been received related to this contract and is reflected as a reduction in the cost of building and improvements on the Condensed Consolidated Balance Sheets, in accordance with applicable accounting guidance.